SPARC Share Price: Ek hi voucher ne kamaal kar diya! Profit ₹1,761 Cr paar, Net Worth positive hui

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorVihaan Mehta|Published at:
SPARC Share Price: Ek hi voucher ne kamaal kar diya! Profit ₹1,761 Cr paar, Net Worth positive hui
Overview

Sun Pharma Advanced Research (SPARC) ne Q4 FY26 mein toofani kamai ki hai! Ek USFDA voucher bech kar company ne **₹1,761 Crore** ka record profit bana liya aur dekhte hi dekhte net worth bhi positive ho gaya. Par haan, thoda debt bhi badha hai.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Aakhir SPARC ne itna paisa kaise kamaya?

Is baar SPARC ke results dekh kar lag raha hai ki company ne record tod diya hai. Q4 FY26 mein inki standalone income 6,722.43% badh kar ₹1,855.02 Crore ho gayi. Aur jab income itni bhadi, toh profit bhi ₹1,760.70 Crore ho gaya! Poore FY26 ki baat karein toh income 2,469.33% badh kar ₹1,890 Crore hui aur profit ₹1,552.13 Crore raha.

Voucher Sale ka Magic!

Is sab kamaai ka sabse bada reason hai ek USFDA Priority Review Voucher (PRV) ki sale, jisse SPARC ko ₹1,840.02 Crore ka ek-baar ka faayda hua. Isi ki wajah se, company ka net worth jo pehle negative tha (₹-220.62 Crore on March 31, 2025), woh ab positive ho kar ₹1,333.58 Crore ho gaya hai. Yeh ek bahut badi financial milestone hai.

Par Chinta ki baat kya hai?

Jab hum results ko thoda aur dekhte hain, toh pata chalta hai ki company ka standalone borrowing (loan) kaafi badh gaya hai. FY26 mein yeh ₹556.14 Crore ho gaya, jo pichhle saal sirf ₹158.19 Crore tha. Toh ek taraf profit bhada, par loan bhi badha.

SPARC ka Business Model aur PRVs?

SPARC ek R&D (Research & Development) firm hai, jahan naye drugs banane mein bahut time aur paisa lagta hai. Inka model operational income se zyada aise bade, kabhi-kabhi hone wale financial events par depend karta hai, jaise yeh voucher sale. USFDA PRVs specially rare diseases ke liye treatments banane walon ko milte hain, aur inhein bech kar company ko achha paisa mil sakta hai.

Aage Investors ko kya dekhna chahiye?

Sabse badi risk yeh hai ki jo profit dikh raha hai woh one-time gain hai. SPARC ko apne R&D pipeline se sustainable revenue banana hoga. Is badhte hue loan ko manage karna bhi ek challenge hoga. Isliye, investors ko sirf yeh ek quarter nahi, balki company ki R&D progress aur future operational earning capacity par bhi dhyaan dena chahiye.

Aam Pharma Companies se kaise alag hai SPARC?

Divi's Laboratories, Laurus Labs, Lupin, aur Cipla jaise pharma peers R&D karte hain, par unke paas usually already chal rahe products se regular income aati rehti hai. SPARC ka current scenario thoda alag hai kyunki iski financial turnaround ek non-operational asset sale se hui hai.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.